Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Filgrastim | Research

A novel PEGylated form of granulocyte colony-stimulating factor, mecapegfilgrastim, for peripheral blood stem cell mobilization in patients with hematologic malignancies

Authors: Jingjing Wen, Qiaolin Zhou, Lin Shi, Fang Xu, Yiping Liu, Jing Su, Ya Zhang, Wen Qu, Jing Yue

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

The Pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) has longer half-life and is given once only, which is more comfortable for patients. We aimed to evaluate the efficacy of mecapegfilgrastim for hematopoietic stem cell (HSC) mobilization in patients with hematologic malignancies and to explore the potential factors related to HSC mobilization.

Methods

A retrospective analysis was performed on patients who underwent HSC mobilization in the hematology department of Mianyang Central Hospital from April 2016 to November 2022. The number of CD34 + cells collected was compared between the patients receiving mecapegfilgrastim (PEG group) and those receiving recombinant human granulocyte colony-stimulating factor (rhG-CSF group), and the possible factors for mobilization failure were analyzed.

Results

The success rates of collecting CD34 + cells in the PEG group and rhG-CSF group were 80.6% and 67.7%, respectively (χ = 1.444, P = 0.229). The median CD34 + cell counts were 3.62 × 10^6/kg and 2.92 × 10^6/kg (P = 0.178), respectively. After combination with plerixafor for mobilization, the median number of CD34 + cells collected in the PEG group and rhG-CSF group were 3.64 × 10^6/kg and 3.92 × 10^6/kg, respectively, with no significant difference (P = 0.754). There was no significant difference in hematopoietic cell recovery or infection between the groups (P > 0.05). Multivariate analysis showed that more than 5 cycles of chemotherapy (OR = 15.897, 95% CI: 1.766-143.127, P = 0.014), a precollection WBC count < 32 × 10^9/L (OR = 14.441, 95% CI: 2.180-95.657, P = 0.006) and a precollection to premobilization lymphocyte ratio < 1.7 (OR = 11.388, 95% CI: 2.129–60.915, P = 0.004) were independent risk factors for HSC mobilization failure.

Conclusions

The HSC mobilization efficacy of mecapegfilgrastim in patients with hematologic malignancies was comparable to that of rhG-CSF, and combination with plerixafor for mobilization was feasible and effective. Patients with more than 5 cycles of chemotherapy before HSC mobilization, a precollection WBC count lower than 32 × 10^9/L, and a precollection lymphocyte count less than 1.7 times the premobilization lymphocyte count have a high probability of HSC mobilization failure.
Appendix
Available only for authorised users
Literature
1.
Chang HH, Liou YS, Sun DS. Hematopoietic stem cell mobilization. Tzu Chi Med J. 2022;34(3):270–5.CrossRefPubMed
2.
Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011;50(5):295–306.CrossRefPubMed
3.
Martino M, Laszlo D, Lanza F. Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization. Expert Opin Biol Ther. 2014;14(6):757–72.CrossRefPubMed
4.
Kuan JW, Su AT, Leong CF. Pegylated granulocyte-colony stimulating factor versus non-pegylated granulocyte-colony stimulating factor for peripheral blood stem cell mobilization: a systematic review and meta-analysis. J Clin Apher. 2017;32(6):517–42.CrossRefPubMed
5.
Watts NL, Marques MB, Peavey DB, Innis-Shelton R, Saad A, Ad S, et al. Mobilization of hematopoietic progenitor cells for autologous transplantation using Pegfilgrastim and Plerixafor: efficacy and cost implications. Biol Blood Marrow Transplant. 2019;25(2):233–8.CrossRefPubMed
6.
Danylesko I, Sareli R, Varda-Bloom N, Yerushalmi R, Shem-Tov N, Magen H, et al. Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation. Int J Hematol. 2021;114(3):363–72.CrossRefPubMed
7.
Lipan L, Colita A, Stefan L, Calugaroiu C, Serban C, Pasca S, et al. Comparison of peripheral blood stem cell mobilization with filgrastim versus pegfilgrastim in lymphoma patients – single center experience. J BUON. 2021;26(3):1080–7.PubMed
8.
Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34 + progenitors in patients with multiple myeloma: PEGFILGRASTIM MOBILIZATION IN MULTIPLE MYELOMA. Transfusion. 2006;46(2):180–5.CrossRefPubMed
9.
Ding X, Huang W, Peng Y, Fan H, Zhu Y, Liu X, et al. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma. Ann Hematol. 2020;99(6):1331–9.CrossRefPubMed
10.
11.
Shen T, Zhao Y. Diagnostic and therapeutic criteria for hematological diseases – 4rd edition. Science Press; 2018.
12.
Giralt S, Costa L, Schriber J, DiPersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus Guidelines and Recommendations. Biol Blood Marrow Transplant. 2014;20(3):295–308.CrossRefPubMed
13.
Wang T, Feng R, Li JT, Ning SY, Yang YZ, Zhang CL, et al. Application of pegylated recombinant human granulocyte colony stimulating factor in mobilization of autologous peripheral blood stem cells. Zhonghua Xue Ye Xue Za Zhi. 2021;42(1):70–3.PubMed
14.
Partanen A, Valtola J, Ropponen A, Kuitunen H, Kuittinen O, Vasala K, et al. Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34 + cells in non-hodgkin lymphoma patients. Transfusion. 2019;59(1):325–34.CrossRefPubMed
15.
Anu P, Antti T, Raija S, Marja P, Jaakko V, Timo S, et al. Comparison of CD34 + cell mobilization, blood graft cellular composition, and post-transplant outcome in myeloma patients mobilized with filgrastim or pegfilgrastim added to low‐dose cyclophosphamide: a prospective multicenter study. Transfusion. 2021;61(11):3202–12.CrossRefPubMed
16.
SHAO S, BAI H, WANG C, WAN L, LIU H. PEG-rhG-CSF for peripheral blood stem cell mobilization in patients with relapsed or refractory malignant lymphoma. Chin J Clin Oncol. 2017;44(13):662–6.
17.
Partanen A, Valtola J, Ropponen A, Vasala K, Penttilä K, Ågren L, et al. Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-hodgkin lymphoma patients mobilizing poorly. Ann Hematol. 2017;96(11):1897–906.CrossRefPubMed
18.
Abid MB, De Mel S, Abid MA, Yap ES, Gopalakrishnan SK, Chen Y, et al. Pegylated Filgrastim Versus Filgrastim for Stem Cell mobilization in multiple Myeloma after Novel Agent induction. Clin Lymphoma Myeloma Leuk. 2018;18(3):174–9.CrossRefPubMed
19.
Skopec B, Skerget M, Zontar D, Zadnik V, Zver S. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients. Wien Klin Wochenschr. 2017;129(15–16):545–51.CrossRefPubMed
20.
Yang SM, Chen H, Chen YH, Zhu HH, Zhao T, Liu KY. Dynamics of monocyte count: a good predictor for timing of peripheral blood stem cell collection. J Clin Apheresis. 2012;27(4):193–9.CrossRefPubMed
21.
Ishii Y, Fujisawa S, Nigauri C, Ando T, Suzuki T, Ogusa E, et al. Peripheral blood Monocyte Count is a predictor of successful peripheral blood stem cell Harvest after Chemo-Mobilization in patients with malignant lymphoma. Indian J Hematol Blood Transfus. 2018;34(2):347–9.CrossRefPubMed
22.
Olivieri J, Attolico I, Nuccorini R, Pascale SP, Chiarucci M, Poiani M, et al. Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. Bone Marrow Transplant. 2018;53(4):461–73.CrossRefPubMed
23.
Lee KH, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, et al. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience. Vox Sang. 2014;107(4):407–15.CrossRefPubMed
24.
Bhamidipati P, Fiala MA, Wang S, Sturgill T, Gao F, Abboud CN, et al. Predicting Autologous Stem Cell Mobilization Failure In Hematologic Malignancies Blood. 2013;122(21):2034.
25.
Zhang H, Fang Z, Yuan S, Qiang H, Ximin L, Ningxia S, et al. Factors influencing the collection of peripheral blood hematopoietic stem cells in patients with autologous hematopoietic stem cell transplantation. J Leuk lymphoma. 2019;28(1):2.
26.
du Toit J, Goeijenbier M, du Toit C, de Witt P, Koornhof H, Oosthuizen J, et al. Predictors of poor haematopoietic stem cell mobilisation in patients with haematological malignancies at a south african centre. Transfus Apher Sci. 2022;61(4):103419.CrossRefPubMed
27.
Bao W, Liu R, Wang F, Zhang J, Gu Y, Xia GH, et al. Clinical analysis of autologous peripheral blood hematopoietic stem cell mobilization regimen in patients with malignant hematological Diseases. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020;28(2):663–8.PubMed
28.
Teipel R, Schetelig J, Kramer M, Schmidt H, Schmidt AH, Thiede C, et al. Prediction of hematopoietic stem cell yield after mobilization with granulocyte-colony-stimulating factor in healthy unrelated donors. Transfusion. 2015;55(12):2855–63.CrossRefPubMed
29.
Chinese Society of Hematology, Chinese Medical Association. Chinese society of clinical oncology (CSCO), lymphoma-treatment Alliance. Consensus of chinese experts on the mobilization and collection of autologous hematopoietic stem cells in lymphoma (2020). Chin J Hematol. 2020;41(12):5.
Metadata
Title
A novel PEGylated form of granulocyte colony-stimulating factor, mecapegfilgrastim, for peripheral blood stem cell mobilization in patients with hematologic malignancies
Authors
Jingjing Wen
Qiaolin Zhou
Lin Shi
Fang Xu
Yiping Liu
Jing Su
Ya Zhang
Wen Qu
Jing Yue
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11197-3

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map

Research

Inference of core needle biopsy whole slide images requiring definitive therapy for prostate cancer

Matters Arising

Kappa statistic considerations in evaluating inter-rater reliability between two raters: which, when and context matters

Research

Hyperthermia inhibits cellular function and induces immunogenic cell death in renal cell carcinoma

Research

Eta polycaprolactone (ε-PCL) implants appear to cause a partial differentiation of breast cancer lung metastasis in a murine model

Research

LRPPRC regulates malignant behaviors, protects mitochondrial homeostasis, mitochondrial function in osteosarcoma and derived cancer stem-like cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits